Results from eribulin study in liposarcomas and leiomyosarcomas published
11 February 2016 | By Victoria White
Eisai's Halaven (eribulin) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action...
List view / Grid view
News
Alzheimer’s disease treatment market to more than double by 2021, says GBI Research
11 February 2016 | By Victoria White
GBI Research says the impressive growth in the treatment market will be primarily driven by increased disease prevalence during the forecast period...
Source BioScience launch the world’s first -70°C walk-in chamber – the Polar50™
Source BioScience, the international Laboratory Services and Products business, has launched a revolutionary -70°C walk-in chamber, the Polar50™. The launch event was held at the Company’s flagship facility in Rochdale, UK and included a captivating presentation by the world’s greatest living explorer, Sir Ranulph Fiennes, who has led numerous expeditions…
Alecensa trial stopped early; meets primary endpoint
10 February 2016 | By Victoria White
The study showed that patients with NSCLC lived significantly longer without disease worsening when treated with Alecensa compared to crizotinib...
Breakthrough Therapy designation for Adaptimmune’s NY-ESO-1-T cell therapy
10 February 2016 | By Victoria White
The Breakthrough Therapy designation was based on the results of a Phase I/II trial in patients with unresectable, metastatic or recurrent synovial sarcoma...
Positive Phase 1b results for Heptares’ HTL9936
10 February 2016 | By Victoria White
HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia...
Pharming extends Ruconest distribution agreement with Cytobioteck
9 February 2016 | By Victoria White
Under the extended agreement, Cytobioteck will also exclusively distribute Ruconest in Argentina, Costa Rica, the Dominican Republic and Panama...
Gilotrif to gain ground in the NSCLC treatment markets outside the US
9 February 2016 | By Victoria White
An analyst from GlobalData says promising clinical trial data for Gilotrif (afatinib) will strengthen the drug’s position in NSCLC treatment markets outside the US...
SMC accepts five new medicines; rejects eculizumab
9 February 2016 | By Victoria White
The committee was unable to accept eculizumab as it was "not considered to represent an effective use of NHS Scotland’s resources"...
James Robinson named as President, Americas Operations for Astellas
9 February 2016 | By Victoria White
Effective from 1st April 2016, Robinson will have responsibility for the company's operations in North and South America...
Executive leadership team named for the combined Allergan Pfizer business
8 February 2016 | By Victoria White
The close of the transaction to combine Pfizer and Allergan is expected in the second half of 2016, and is subject to certain conditions...
BIO-Europe Spring® 2016 Event in Sweden this April will bring 2,000+ life science executives to Stockholm-Uppsala region
8 February 2016 | By EBD Group
The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4–6, 2016...
RedHill Biopharma and IZI enter RP101 collaboration
8 February 2016 | By Victoria White
The research collaboration will test RP101 in preclinical oncology models in combination with standard-of-care chemotherapies to support existing Phase I and Phase II clinical data...
New toolkit informs of the risks of taking valproate during pregnancy
8 February 2016 | By Victoria White
Valproate is associated with a risk of birth defects and developmental disorders in children born to women who take the treatment during pregnancy...
NICE says ‘no’ to alirocumab in draft guidance
8 February 2016 | By Victoria White
NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...
